PD-L1 Biomarker for Immunotherapy
To qualify for Tecentriq®-based immunotherapy, the cancer must test positive for the PD-L1 protein. Learn what researchers have found about PD-L1 and other biomarkers to identify patients suited for immunotherapy.
PAST ARTICLES
2020
2019
- Tips for Reading Cancer News
- What is a Tumor Agnostic Therapy?
- Treating Brain Metastases
- New FDA Approval: A PI3K Inhibitor
- Best of MBC Research News (2018-2019)
- What is Oligometastatic Breast Cancer?
- Getting to the Target: Antibody Drug Conjugates
- First Immunotherapy Approved for MBC
- Liquid Biopsies: More than a Blood Test?
- Get the Latest News on PARP Inhibitors
- New Research Presented at San Antonio
SEARCH OUR SITE
for past articles or specific information.